Hematologic Malignancies

A Once-Daily Tablet Joins the Ruxolitinib Franchise

George Padron
Oncology Care, Healthcare Headlines, Hematologic Malignancies | May 2, 2026
Once-daily 55 mg Jakafi XR is bioequivalent to twice-daily 25 mg Jakafi. Indications, pharmacology, and safety profile are unchanged from the original product.

Digital Symptom Monitoring in Blood Cancer Patients Cuts Hospitalizations and Costs

George Padron
Oncology Care, AI & Critical Decision Support, Remote Patient Monitoring, Digital Therapeutics, Hematologic Malignancies | Apr 20, 2026
A 1,645-patient retrospective study found ePRO-based remote therapeutic monitoring reduced infection-related ED visits 34% and hospital admissions 52%, saving nearly $1M per 1,000 patients per year.

ASH Clinical Trial Map Could Streamline Evidence for Payers

George Padron
Oncology Care, Healthcare Headlines, Clinical Guidelines & Standards, Hematologic Malignancies | Apr 17, 2026
New ASH interactive tool and companion toolkit aim to improve clinical trial quality and diversity in hematology, with implications for payer evidence needs.

Hematologic Malignancies

A Once-Daily Tablet Joins the Ruxolitinib Franchise

Digital Symptom Monitoring in Blood Cancer Patients Cuts Hospitalizations and Costs

ASH Clinical Trial Map Could Streamline Evidence for Payers

Latest News

Dr. Eleonora Teplinsky on ASCO 2026 GLP-1 and Breast Cancer Prevention Data

Study Finds Parkinson's Genetic Yield Varies from 0.4% to 10.7% Based on Ancestry

Merck's Oral PCSK9 Inhibitor Approval Undercuts Injectables

Air Quality Alerts Blanket the Northeast as Canadian Smoke Pushes the AQI Into the Unhealthy Band

Care Partners Often Overlooked Patient Portal Users

Who We Are

Connect